QCOR Questcor Pharmaceuticals, Inc.

  • STOCK
  • QCOR
  • Price as of: Aug 14, 08:55 PM EST
  • $93.60
  • +$1.52
  • +1.7%
  • Industry
  • Biotechnology
Share
Questcor Pharmaceuticals, Inc. (QCOR) stopped trading Aug 14, 2014. QCOR was acquired by pharmaceutical maker Mallinckrodt in a $5.8 billion deal.

QCOR Stock Dividend Data

Add QCOR to Watchlist
  • Dividend Yield
    0.00% Healthcare Average 1.01%
  • Annualized Payout
    $0.00  
  • Payout Ratio
    0.0% EPS $7.19
  • Dividend Growth
    3 yrs Since 2013
  • Get QCOR DARS™ Rating

Looking to buy or sell QCOR?

Buy Now
Sell Now
Upcoming Dividend Payouts

QCOR Upcoming Dividend Payouts

QCOR has not yet officially announced its next dividend payout.
DARS Rating™ Breakdown

Dividend.com DARS Rating™ Breakdown for QCOR

Sign Up
Metric QCOR Rank QCOR Avg Ranking Notes
Relative Strength 1 year return is slightly above Benchmark/Peers/Broader Market/Analyst Expectations
Overall Yield Attractiveness Yield is at par with Benchmark/Peers/Broader Market/Analyst Expectations
Dividend Reliability Above average payout ratio. Slightly higher than Benchmark/Peers/Broader Market/Analyst Expectations
Dividend Uptrend Dividends are above average, growing as per Benchmark/Peers/Broader Market/Analyst Expectations
Earnings Growth EPS growth is above average against Benchmark/Peers/Broader Market/Analyst Expectations
DARS Rating Sign Up For DARS Ratings

Brought to You by Mitre Media

Growth History

QCOR Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
NA% NA% 3 years
Reveal More Dividend Growth History for QCOR
Historical Annual Dividend Data & Growth

QCOR Historical Annual Dividend Data & Growth

Payout Amount Calendar Year Annual Growth
$0.9000 2014 12.5%
$0.8000 2013 100.0%
$0.4000 2012 NA
Historical Dividend Data

QCOR Dividend History

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.3000 2014-04-07 2014-06-27 2014-07-01 2014-07-08 Yes Regular Quarter
$0.3000 2014-02-14 2014-04-15 2014-04-18 2014-04-25 Yes Regular Quarter
$0.3000 2013-12-11 2014-01-15 2014-01-17 2014-01-24 Yes Regular Quarter
$0.3000 2013-10-10 2013-10-18 2013-10-22 2013-10-30 Yes Regular Quarter
$0.2500 2013-05-29 2013-07-18 2013-07-22 2013-07-30 Yes Regular Quarter
$0.2500 2013-02-26 2013-04-18 2013-04-22 2013-04-30 Yes Regular Quarter
$0.2000 2012-12-04 2012-12-12 2012-12-14 2012-12-21 Yes Regular Quarter
$0.2000 2012-09-28 2012-10-29 2012-10-31 2012-11-15 Yes Regular Quarter
5-for-2 1995-04-20 1995-05-09 1995-05-01 1995-05-08 NM Stock Split NM

Knowledge Centers

Company Profile

QCOR Company Profile

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology

Questcor Pharmaceuticals, Inc. (QCOR) manufactures prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Acthar Gel for the treatment of the above mentioned diseases, as well as rheumatology-related conditions. In addition, QCOR offers Doral for the treatment of insomnia. The company sells its Acthar primarily to specialty pharmacies, and Doral to pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California. Most of Questcor Pharmaceuticals’ profits are derived from Acthar, and new and existing competitors to Acthar may reduce or eliminate Questcor’s commercial opportunity. Questcor Pharmaceuticals has been paying dividends since 2012 and has increased them consecutively annually since then. Questcor Pharmaceuticals pays its dividends quarterly.

High Yield Stocks

High Yield Stocks

Looking for dividend stocks with great yields? Visit our list of:

High Yield Dividend Stocks
News

Questcor Pharmaceuticals, Inc. News

  • Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
  • Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
  • Ex-dividend dates are very important to dividend investors, since you must purchase a stock prior to its ex-dividend date in order to receive its...
  • These were some of the biggest dividend stock performers on the upside and the downside in today's market action. Highlights Nu Skin...
  • On Monday morning, it was announced that Mallinckrodt plc (MNK) has entered into an agreement with Questcor Pharmaceuticals, Inc () that will...
  • After the bell on Tuesday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings...
  • Goldman Sachs Initiates Coverage on Questcor Pharmaceuticals (QCOR)

    Goldman Sachs reported on Tuesday that it has started coverage on Questcor Pharmaceuticals Inc (QCOR) . The firm has initiated coverage on QCOR with a "Neutral" rating and $71 price target. This price target suggests a 8% upside from the stock's current price of $65.27. An analyst from the firm noted: "We are confident in the continued growth of Acthar by expanding further in new indications, and we believe the deal for Synacthen helped ensure the sustainability of the franchise and removed a key overhang on the stock." "However, given the recent very strong run in the stock and the current valuation, we're taking a more cautious stance on risk/reward for being an aggressive buyer here. We think there are a number of factors that could cause some downward volatility in the stock, and we would be opportunistic and look for a better entry point," added the analyst. Questcor Pharmaceuticals shares were mostly flat during pre-market trading Tuesday. The stock is up 144% YTD.

    The Bottom Line

    Shares of Questcor Pharmaceuticals Inc (QCOR) have a 1.53% yield based on Monday's closing price of $65.27. Questcor Pharmaceuticals Inc (QCOR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • Questcor Pharmaceuticals Upgraded at BofA/Merrill Lynch (QCOR)

    On Wednesday, Bank of America/Merrill Lynch reported that it has raised its rating on pharmaceutical company Questcor Pharmaceuticals Inc (QCOR) . The firm has upgraded QCOR from "Neutral" to "Buy," and has given the company an $80 price target. This price target suggests a 19% upside from the stock's current price of $64.95. Analysts have upgraded the stock due to increased Acthar sales, which are driving growth. Questcor Pharmaceuticals' shares are up $3.35, or 5.16%, during pre-market trading Wednesday. The stock is up 143% YTD. The Bottom Line Shares of Questcor Pharmaceuticals Inc (QCOR) have a 1.54% yield based on Tuesday's closing price of $64.95. Questcor Pharmaceuticals Inc (QCOR) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • Questcor Crushes Analysts' Q2 Estimates (QCOR)

    Questcor Pharmaceuticals (QCOR) beat analyst expectations after reporting for Q2 after the bell on Tuesday afternoon. With the average expectations for Questcor EPS at $1 and revenue at $168.98, the company has far exceeded these estimates. With EPS at $1.35 and revenue at $196.1 million, President and CEO Don M Bailey is looking at the increased use of Acthar as the root cause of this jump in earnings. HP Acthar Gel is a highly purified preparation of ACTH, which is used to battle the effects of multiple sclerosis, and is a growing product in Questcor's line up; the company shipped 7050 vials in the last quarter, almost 50% more than Q2 of 2012. Questcor's shares were up 89 cents, or 1.74% at the end of trading Tuesday. The company's shares are up a massive 96.3% YTD. The Bottom Line Shares of Questcor Pharmaceuticals (QCOR)  have a dividend yield of 1.93% based on Tuesday's closing price of $51.91 and its annualized dividend yield of $1. Questcor Pharmaceuticals (QCOR)  is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story
  • Questcor Adds Former Shire CEO To Board (QCOR)

    Today, Questcor Pharmaceuticals Inc (QCOR) announced its newest addition to its board of directors: former CEO of Shire PLC, Angus C. Russell. Russell held his position as CEO for five years at Shire, another biopharmaceutical company, and was also an executive for ICI, Zeneca and AstraZeneca. Shares of Questcor Pharmaceuticals closed 1.14% higher during Monday's session. Year-to-date, the stock is up 39.63%. The Bottom Line Questcor Pharmaceuticals, Inc. (QCOR)  has a 2.72% yield, based on Monday's closing price of $36.71. Questcor Pharmaceuticals, Inc. (QCOR)  is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.3 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
    Expand to read the full story